$4.990
-0.211 (-4.22%)Zum Schluss
PAVM-News
PAVM-Events
Lucid Diagnostics' EsoGuard Test Recognized by Concert Coverage Policy
Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive coverage policy effective July 2026 for non-invasive screening of esophageal precancer and cancer. Concert establishes coverage policies that its client health plans can adopt. The policy cites sufficient evidence in published guidelines and peer-reviewed literature to definitively demonstrate improved health outcomes, and considers Lucid's EsoGuard Esophageal DNA Test medically necessary in patients who meet American College of Gastroenterology screening criteria.
PAVmed Trading Halted Due to Volatility
PAVmed trading halted, volatility trading pause
PAVmed Trading Resumes
PAVmed trading resumes
PAVmed Reports Q1 Revenue of $22 Million
Reports Q1 revenue $22,000 vs. $8,000 last year. PAVmed had cash and cash equivalents of $6.5M as of March 31, compared to $1.5M as of December 31, 2025. "PAVmed now has a significantly simplified capital structure and strengthened balance sheet, positioning the Company to focus on execution across our core businesses and evaluate additional asset acquisition opportunities aligned with our long-term growth strategy," said Lishan Aklog, PAVmed's Chairman and CEO. "Veris continues to expand its commercial engagement with OSU-The James while progressing development of its implantable physiological monitor toward FDA submission, and Lucid continues to build commercial momentum for EsoGuard with a strengthened balance sheet pending Medicare coverage. We are also actively advancing multiple technologies within our relaunched medical device portfolio under Joseph Virgilio's leadership, while increasingly leveraging his experience building and scaling growth-stage businesses."
PAVmed Files to Sell 9.23M Shares of Common Stock
PAVmed files to sell 9.23M shares of common stock for holders
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.